Barr Allegra-D Generic Receives Final Approval

A launch of the generic fexofenadine/pseudoephedrine combination would be "at risk" because of ongoing patent litigation with Sanofi-Aventis. Final ANDA approval follows resolution of a dispute between Barr and FDA over 180-day exclusivity for the product.